Monoclonal antibodies are becoming the backbone of treatments for relapsed and refractory patients, but they are also making their way into the front-line setting for newly diagnosed patients. The first official day of the American Society of Hematology (ASH) Annual Conference was filled presentations, posters, and exhibits touting the effectiveness of this drug class. I would […]